Avalere Health’s Post

Blocking bile acid reabsorption in the kidney may alleviate cholestatic-associated cholemic nephropathy Cholemic nephropathy (CN) represents a severe complication of cholestasis and remains an unmet clinical challenge. This study, published in the Journal of Hepatology, utilized an experimental mouse model of obstructive cholestasis (BDL mice) to demonstrate that proximal tubular epithelial cells (TECs) absorb and accumulate bile acids (BAs) through the apical sodium-dependent bile acid transporter (ASBT), resulting in kidney damage. Significantly, the inhibition of renal ASBT by AS0369 prevented kidney injury, arising as a novel therapeutic strategy for CN. #OpenAccess here: https://lnkd.in/dDR32gat Ahmed Ghallab EASL | The Home of Hepatology

GLP-1 receptor agonists surged in 2023, with a 352% rise in prescriptions. With these treatments reshaping the obesity and diabetes landscape, hepatology experts IHEP (International Hepatology Education Program) ask what the impact could be for metabolic dysfunction-associated steatohepatitis. Learn their insights and find out how the treatment landscape is changing: https://bit.ly/3vLfgJM #AvalereHealth #Hepatology #MedicalInnovation #MASH #NASH #GLP1

🔬💡 Exciting News in Hepatology! Our latest study uncovers the role of ZBP1 in hepatocyte pyroptosis during acute liver injury (ALI)! 🧬🔥 Key Findings: ZBP1's involvement in hepatocyte death pathways investigated Insights into ALI's pathogenesis and systemic inflammatory responses Mitochondrial damage and NLRP3 inflammasome activation explored Read the full study here: https://lnkd.in/gura8nby #Hepatology #LiverInjury #Pyroptosis #MedicalResearch #ZBP1 #ROS #ScienceLinkedIn 📚🔬

Our hepatology experts, IHEP (International Hepatology Education Program), ask what the impact of GLP-1s could be for metabolic dysfunction-associated steatohepatitis. Read their insights: https://bit.ly/3vLfgJM

Recently, I had the privilege of meeting a woman who spent decades awaiting a diagnosis for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease. This is not just her story. More than 115 million people around the world are living with MASH. Why should we pay attention to this? Due to progressive liver damage that can develop silently, MASH can often go undiagnosed for years. MASH is projected to become the leading cause of liver transplantation by 2030. Each delayed diagnosis is a missed opportunity for early intervention and improved patient outcomes. This underscores the urgent need for innovation in MASH. It is through such advancements that we could transform patient stories from journeys of uncertainty to narratives of hope and healing. Let's continue to push the boundaries of what's possible in healthcare, for the sake of patients worldwide. Today’s announcement of potential best-in-class data is pivotal in our mission to improve the lives of people living with MASH and liver fibrosis. I’m proud of the team for achieving this critical Phase II milestone! #EASLCongress #liverdisease #NEWS

Hepatocellular senescence plays an important role in the pathogenesis of non‑alcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH). At Gubra, we have recently profiled the molecular signature of hepatocellular senescence in the GAN DIO-NASH mouse. Notably, the therapeutic benefits of long-term dietary intervention (chow reversal for up to 24 weeks) are reflected by effective clearance of senescent hepatocellular cells in the model. The translational biopsy-confirmed GAN DIO-NASH mouse model is highly applicable for profiling senotherapeutics targeted for NASH/MASH. Read the paper in BMC Gastroenterology https://lnkd.in/di7REVnC. To learn more, reach out to Gubra VP Michael Feigh. #MASH #NASH #hepatocellularsenescence #liverfibrosis #drugdiscovery #senolytics

GAN DIO-NASH mouse model for hepatocellular senescence - New paper! In a great collaboration with Novo Nordisk and University of Copenhagen (Københavns Universitet), we are happy to present a new paper in our biopsy-confirmed GAN DIO-NASH mouse model. Demonstrating a molecular signature of hepatocellular senescence and the effect of dietary intervention (for up to 24 weeks) for reversing markers of hepatocellular senescence in conjunction with fibrosing NASH. First step accomplished, being to establish a hepatic signature of "aging" in the context of NASH and demonstrate efficacy of dietary intervention. Next step would be to explore senotherapeutics in our biopsy-confirmed GAN DIO-NASH mouse model. Stay tuned! Below the paper for you to download!

🌟 Hope For The Week: Study from 2018 in Journal of Hepatology on hypothermic oxygenated perfusion (HOPE) for liver transplants compared 50 HOPE-treated DCD liver transplants with standard DBD transplants and untreated DCD livers. Despite longer donor warm ischemia, HOPE-treated livers had 94% 5-year graft survival, similar to standard DBD livers, and significantly better than untreated DCD livers (78%). This suggests HOPE is a highly effective method to improve outcomes for high-risk liver grafts.

📣 There is no approved treatment for Acute-on-Chronic Liver Failure (#ACLF), a life-threatening condition with an extremely high sense of emergency for patients, clinicians, regulators and payers. Our pipeline includes five assets in development to address ACLF and its complications. 📍 We will be present at the #EASL congress to talk about ACLF via 3 events and 2 scientific posters: 🎤 EF CLIF and GENFIT partnership event 🎤 UNVEIL-IT® Investigator Meeting 🎤 ELPA educational training event 📊 Poster #1: blood and peritoneal metabolomics suggest VS-01 actively captures metabolites associated with ACLF 📊 Poster #2: Nitazoxanide directly protects from stress-induced cell death to alleviate liver damage in preclinical models of ACLF 👉 Read more on our Press Release: https://lnkd.in/e5FMvpdy 🎬 See the full ACLF video: https://lnkd.in/ene_QTwV EASL | The Home of Hepatology European Foundation for the Study of Chronic Liver Failure (EF CLIF) European Liver Patients' Association - ELPA #EASLCongress #Hepathology #LiverDisease #MultipleOrganFailures #RareDisease #LiverFailure #Cirrhosis

Happy to share our recent review article on “Therapeutic Plasma Exchange in Hepatology: Indications, Techniques & Practical application” in Journal of Clinical & Experimental Hepatology ⭐️ Especially useful all those looking after patients with Liver diseases! 👍 https://lnkd.in/gJW4uYTD